RCG Holdings
STRONG BUYUnaffected by the credit crisis, thriving in the fast growing global biometrics and RFID market and highly profitable, RCG remains curiously overlooked by investors.
Interim results to June from the Asia Pacific-focused products and services provider showed impressive 65% sales growth to £63.9m, delivered largely organically, from which pre-tax profits powered ahead from £12.1m to £20.9m. A further highlight was cash conversion, which improved substantially from 39% to 70%.
‘Security concerns are still around and will continue to help us,’ says chairman and chief executive Raymond Chu, upbeat about the recent acquisitions of Chance Best and Vast Base, the Singapore-based RFID technology provider with good links into the Chinese event ticketing and healthcare sectors.
In May, RCG spent £27m acquiring a further 40.1% interest in Vast Base, increasing its stake to 60%. The ambitious Chu also sees recent OEM agreements with Acer and NEC fuelling growth.
Already established in Southeast Asia, Greater China and the Middle East, he says RCG continues to expand, albeit at cautious pace, into new markets such as the US and Japan.
For December 2008, house broker Investec Securities forecasts a jump in pre-tax profits from £29.3m to £42.7m from a top line £132m. For December 2009, profits of £50.1m from £155m sales look achievable, sending earnings up from 17.3p to 18.8p per share.
On those estimates, RCG, shortly to dual list on the Hong Kong Stock Exchange to widen its investor base and increase liquidity, trades on budget 2008 and 2009 earnings multiples of 3.7 and 3.47, which look particularly and rather inexplicably ungenerous.
- Reduce text size Decrease text size
- Increase text size Increase text size
- Print article Print
- Share this article Share
- Email article to a friend Email
Market cap: £151.13m
PE Forecast: 3.7
Share price: 65.25p
Subscribe today
More breaking news stories.
More extended feature articles.
And a depth of analysis you
can't find anywhere else.
Advertisement
VCT Report 2010
VCT Report 2010 uncovers the money available
for investment in every single VCT, helping you get one step ahead in the race to attract funding for your unquoted, AIM-listed or PLUS-quoted
company.
Order VCT Report 2010 today using this online form
Cash Shells Directory 2010
A comprehensive overview of cash shells on AIM and PLUS, companies that have become a significant feature on the market landscape. For more information and to order, click here or contact our marketing team on 020 7250 7056.
Coverage of AIM, techMARK and PLUS Markets
Informative features and research on fast-growing companies, small-cap and growth stocks, penny shares, stock market tips and share recommendations, directors' dealings, company news and analysis, new issues and upcoming IPOs.
Take control of your investments
A full year's subscription to What Investment magazine for £19.95, a whopping 58% off. Get the latest news, features and expert advice on ISAs, Investment Trusts and Funds, SIPPS, Investing for Children and much much
more. Find out more here.
The Financial Times Guide to Personal Tax
is the definitive and most up-to-date guide to completing your self-assessment tax return, making sure that you get it right and on time, and showing how you can save tax. For more information and to order, click here or contact our marketing team on 020 7250 7056.
The AIM Guide Spring 2010
The new, fully updated AIM Guide is now available to buy for only £49.95 (saving you £30).
A 'must-have' for any serious investor or professional interested in the market for young, fast-growing companies. Order your copy today Hurry, as offer ends soon!
Share recommendations and small-cap stock picks
Small-cap and growth company share recommendations on AIM- and PLUS-listed companies. Latest analysts' stock tips and advice on which are the best shares to buy on London's junior stock markets.
Popular Recommendations
Advertisement
Latest Recommendations
Delcam 01/09/2010
Delcam, the international seller of CAD/CAM software to the engineering, aerospace and healthcare sectors among others, is a cash-generative small-cap seeing recovery in its markets.
Antisoma 01/09/2010
Bombed-out biotech play Antisoma is hoping two of its drugs will lead to good fortune after experiencing disaster with lung cancer treatment ASA404.
The Capital Pub Company 31/08/2010
London pub operator The Capital Pub Company is seeing continuing sales growth on the back of a surprisingly resilient market.
Sectors
